Project Grant R44CA295173
Award Date
9/4/24
Completion Date
8/31/26
Dollars Obligated
$2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02109, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
The University of California, Davis was awarded a $615,399 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a transformable nanoparticle (TNP) platform capable of transforming into nanofibrillar networks that can effectively deliver immunomodulatory peptides, small molecules, and proteins to the tumor microenvironment. This 5-year research project aims to optimize the TNP/TCTS therapeutic platform for on-demand modulation of the tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $3,157,784 Project Grant to Synthis Therapeutics, Inc. to conduct in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) analysis of SYN101, a first-in-class immune cell-targeted TGFβ therapy for cancer patients. The goals of the 22-month project are to: 1) test the efficacy of SYN101 in humanized mouse tumor models and define the comprehensive immune response, and...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the tumor suppressive potential of an antisense RNA (asRNA) candidate, CDH3-AS1, and investigate its role in regulating melanocyte transformation and melanoma formation. The $433,256 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund the development of genetic tools to modulate the expression of CDH3-AS1 and evaluate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted Aurora-A kinase (AURKA) inhibitor, NN-01-195. The goal is to establish the mechanism of action for NN-01-195 and evaluate its in vivo tumor accumulation and efficacy, benchmarking it against two parental compounds - the AURKA inhibitor TAS-119 and the HSP90 inhibitor SNX-2112. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Promilead, LLC to evaluate a small-molecule compound, USCYL01, as a potential therapy to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) assess the toxicity and pharmacokinetic properties of USCYL01 in vitro and in vivo, and 2) test USCYL01 as an adjunct to ICI plus...